HAPPY EASTER! 50% Off Premium Subscription Claim Offer ⏰ 0d 00h 00m 00s

BioMarin Pharmaceutical. Earnings Calls

Q1 2025 (Upcoming)
Release date Apr 23, 2025
EPS estimate $0.95
EPS actual -
Revenue estimate 741.646M
Revenue actual -
Expected change +/- 2.68%
Q4 2024 Beat
$0.92 (70.37%)
Release date Feb 19, 2025
EPS estimate $0.540
EPS actual $0.92
EPS Surprise 70.37%
Revenue estimate 712.298M
Revenue actual 747.313M
Revenue Surprise 4.92%
Q3 2024 Beat
$0.91 (16.67%)
Release date Oct 29, 2024
EPS estimate $0.780
EPS actual $0.91
EPS Surprise 16.67%
Revenue estimate 712.35M
Revenue actual 745.74M
Revenue Surprise 4.69%
Q2 2024 Beat
$0.96 (168.31%)
Release date Aug 05, 2024
EPS estimate $0.358
EPS actual $0.96
EPS Surprise 168.31%
Revenue estimate 663.978M
Revenue actual 708.658M
Revenue Surprise 6.73%

Last 4 Quarters for BioMarin Pharmaceutical.

Below you can see how BMRN performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

Q2 2024 Beat
Release date Aug 05, 2024
Fiscal end date Jun 30, 2024
Price on release $80.47
EPS estimate $0.358
EPS actual $0.96
EPS surprise 168.31%
Date Price
Jul 30, 2024 $84.39
Jul 31, 2024 $84.33
Aug 01, 2024 $84.62
Aug 02, 2024 $84.20
Aug 05, 2024 $80.47
Aug 06, 2024 $86.87
Aug 07, 2024 $86.30
Aug 08, 2024 $87.90
Aug 09, 2024 $88.64
4 days before -4.65%
4 days after 10.15%
On release day 7.95%
Change in period 5.04%
Q3 2024 Beat
Release date Oct 29, 2024
Fiscal end date Sep 30, 2024
Price on release $69.91
EPS estimate $0.780
EPS actual $0.91
EPS surprise 16.67%
Date Price
Oct 23, 2024 $69.98
Oct 24, 2024 $70.39
Oct 25, 2024 $69.73
Oct 28, 2024 $70.13
Oct 29, 2024 $69.91
Oct 30, 2024 $66.68
Oct 31, 2024 $65.89
Nov 01, 2024 $66.60
Nov 04, 2024 $66.01
4 days before -0.100%
4 days after -5.58%
On release day -4.62%
Change in period -5.67%
Q4 2024 Beat
Release date Feb 19, 2025
Fiscal end date Dec 31, 2024
Price on release $65.61
EPS estimate $0.540
EPS actual $0.92
EPS surprise 70.37%
Date Price
Feb 12, 2025 $65.86
Feb 13, 2025 $64.42
Feb 14, 2025 $64.85
Feb 18, 2025 $64.86
Feb 19, 2025 $65.61
Feb 20, 2025 $68.71
Feb 21, 2025 $68.25
Feb 24, 2025 $69.01
Feb 25, 2025 $71.17
4 days before -0.380%
4 days after 8.47%
On release day 4.72%
Change in period 8.06%
Q1 2025 (Upcoming)
Release date Apr 23, 2025
Fiscal end date Mar 30, 2025
Price on release -
EPS estimate $0.95
EPS actual -
Date Price
Apr 11, 2025 $56.82
Apr 14, 2025 $59.67
Apr 15, 2025 $60.02
Apr 16, 2025 $58.82
Apr 17, 2025 $59.17

BioMarin Pharmaceutical. Earnings Call Transcript Summary of Q4 2024

Key Initiatives

Key initiatives included prioritizing pipeline candidates, reorganizing operations into business units, and implementing a $500 million cost transformation program.

Financial Highlights

  • Total revenues for 2024 increased by 18% year-over-year to $2.85 billion.
  • Non-GAAP operating margin expanded by over 900 basis points, reaching 28.6%, while non-GAAP diluted earnings per share rose by 69% to $3.52.
  • In the fourth quarter, revenues grew by 16% to $747 million, driven significantly by VOXZOGO’s performance.

Product Performance

  • VOXZOGO for achondroplasia grew 56% year-over-year, revenue of $735 million, with plans for expansion into other skeletal conditions by 2027.
  • Enzyme Therapies (totaling ~ $1.9 billion for 2024) achieved a 12% year-over-year growth, indicating durability in the core enzyme business.

Pipeline and Clinical Developments

  • Advancements expected in 2025, with data releases anticipated for the Duchenne muscular dystrophy (DMD) program (BMN 351), a long-acting CNP (BMN 333), and an age expansion study for PALYNZIQ.
  • BioMarin aims for clinical results by mid-2025 that could significantly impact treatment landscapes in DMD and PKU.

2025 Guidance

  • Projected total revenues between $3.1 billion and $3.2 billion, representing a growth of 10% compared to 2024.
  • Non-GAAP operating margin expected to be between 32% and 33%, driven by continuous revenue growth and cost transformation initiatives.
  • Non-GAAP diluted earnings per share expected between $4.20 and $4.40.

Business Development Strategy

  • Commitment to responsibly pursuing business development opportunities focused on genetically defined conditions, particularly in skeletal and enzyme therapies.
  • Open to preclinical and clinical assets to enhance long-term growth prospects.

Future Outlook

  • BioMarin is focusing on expanding treatment access to over 60 countries by 2027, driven primarily by VOXZOGO and new innovations.
  • Continued emphasis on building commercial expertise, increasing field personnel, and leveraging existing commercialization strategies to enhance growth prospects.

Investor Takeaway

  • BioMarin's strong financial performance and strategic initiatives place it on a robust growth trajectory, with promising pipeline advancements and a solid position in established markets.
  • Investors should monitor the upcoming clinical data releases and the company's strategic moves in the competitive landscape for both VOXZOGO and enzyme therapy products.

BioMarin Pharmaceutical. Earnings History

Earnings Calendar

FAQ

When is the earnings report for BMRN?
BioMarin Pharmaceutical Inc. (BMRN) has scheduled its earnings report for Apr 23, 2025 before the markets open.

What is the BMRN price-to-earnings (P/E) ratio?
BMRN P/E ratio as of Apr 17, 2025 (TTM) is 26.28.

What is the BMRN EPS forecast?
The forecasted EPS (Earnings Per Share) for BioMarin Pharmaceutical Inc. (BMRN) for the first fiscal quarter 2025 is $0.95.

What are BioMarin Pharmaceutical Inc.'s retained earnings?
On its balance sheet, BioMarin Pharmaceutical Inc. reported retained earnings of $747.31 million for the latest quarter ending Dec 31, 2024.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT BIOMARIN PHARMACEUTICAL INC.
BioMarin Pharmaceutical.
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form o...
GOLDEN STAR
Ticker Change Signal Date
F
FNA
$12.99
0.85% Apr 15
V
VCSH
$78.34
0.370% Apr 15
F
FTSM
$59.85
0.117% Apr 15
S
SLQD
$49.97
0.260% Apr 15
I
ISTB
$48.11
0.239% Apr 15

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE